Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Trial Title: Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT05673967

Condition: Relapsed and Refractory Multiple Myeloma (RRMM)

Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell

Conditions: Keywords:
Real-World Outcomes
Multiple Myeloma (MM)
Objective response rate (ORR)
Triple-class exposed (TCE)
Triple-class refractory (TCR)
Progression-free survival (PFS)
Overall survival (OS)

Study type: Observational

Overall status: Active, not recruiting

Study design:

Time perspective: Retrospective

Intervention:

Intervention type: Other
Intervention name: Non-Interventional
Description: No study treatment will be administered on this study.
Arm group label: Cohort 1

Summary: Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after meeting the following criteria: (1) have either (a) at least three prior lines (3L) and are triple-class exposed (TCE), or (b) are triple-class refractory (TCR), and (2) meet similar inclusion/exclusion criteria to patients in phase 2 cohort 2 of the R5458-ONC-1826 (NCT03761108) trial. Secondary Objectives: 1. To describe additional outcomes (duration of response [DOR], progression-free survival [PFS], overall survival [OS], and time to next treatment [TTNT]) in the same Benchmark Cohort population described in the primary objective. 2. To describe distribution of treatment regimens, ORR, DOR, PFS, OS, and to compare ORR, PFS, OS, and TTNT in an Analysis Cohort consisting of real-world patients derived from the Benchmark Cohort described above who are weighted to align with the characteristics of patients in phase 2 cohort 2 of the R5458-ONC-1826 (NCT03761108) trial. Comparative analyses of PFS and OS will be performed conditional on sufficient maturity of survival data in the R5458-ONC-1826 (NCT03761108) trial at the time of analysis.

Criteria for eligibility:

Study pop:
Patients with RRMM who have either at least three prior lines of therapy (LOT) and are triple-class exposed (3L+/TCE), or are triple-class refractory (TCR).

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1 at baseline 2. Confirmed diagnosis of active MM by IMWG diagnostic criteria 3. Have myeloma that is response-evaluable with measurable disease by M-protein in serum or urine as specified in the IMWG response criteria. 4. Triple-class exposed or refractory Exclusion Criteria: 1. Diagnosis of plasma cell leukemia, primary systemic light-chain amyloidosis (excluding myeloma-associated amyloidosis), Waldenström macroglobulinemia, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin (POEMS) changes syndrome 2. Known MM brain lesions or meningeal involvement 3. History of neurodegenerative condition, central nervous system (CNS) movement disorder, or seizure 4. Cardiac ejection fraction <40% by echocardiogram or multi-gated acquisition scan (MUGA) (or a diagnosis of congestive heart failure, cardiomyopathy, or valvular heart disease as a potential proxy) 5. Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent 6. Live or live attenuated vaccines 7. Treated with B-cell maturation antigen (BCMA)-directed immunotherapies (BCMA antibody-drug conjugates are not excluded). Note: Other protocol-defined Inclusion/Exclusion criteria apply

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Regeneron Research Facility

Address:
City: Tarrytown
Zip: 10591
Country: United States

Start date: January 9, 2023

Completion date: December 20, 2024

Lead sponsor:
Agency: Regeneron Pharmaceuticals
Agency class: Industry

Source: Regeneron Pharmaceuticals

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05673967